Article ID Journal Published Year Pages File Type
4347891 Neuroscience Letters 2009 5 Pages PDF
Abstract

Amyloid β protein (Aβ) is thought to be responsible for the loss of memory in Alzheimer's disease (AD). A significant decrease in [Arg8]-vasopressin (AVP) in the AD brain has been found. However, it is unclear whether the decrease in AVP is involved in Aβ-induced impairment of memory and whether AVP can protect against Aβ-induced neurotoxicity. The present study examines the effects of intracerebroventricular (i.c.v.) injection of AVP on hippocampal long-term potentiation (LTP), a synaptic model of memory, and investigates the potential protective function of AVP in Aβ-induced LTP impairment. The results showed that (1) i.c.v. injection of different concentrations of AVP or Aβ25–35 did not affect the baseline field excitatory postsynaptic potentials (fEPSPs); (2) AVP administration alone induced a significant increase in HFS-induced LTP, while Aβ25–35 significantly suppressed HFS-induced LTP; (3) Aβ25–35-induced LTP suppression was significantly prevented by the pretreatment with AVP; (4) paired-pulse facilitation did not change after separate application or co-application of AVP and Aβ25–35. These results indicate that AVP can potentiate hippocampal synaptic plasticity and dose-dependently prevent Aβ25–35-induced LTP impairment. Thus, the present study provides further insight into the mechanisms by which Aβ impairs synaptic plasticity and suggests an important approach in the treatment of AD.

Related Topics
Life Sciences Neuroscience Neuroscience (General)
Authors
, , , , ,